Mutual of America Capital Management LLC raised its stake in shares of Akebia Therapeutics Inc (NASDAQ:AKBA) by 16.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 130,179 shares of the biopharmaceutical company’s stock after acquiring an additional 18,779 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Akebia Therapeutics were worth $1,936,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AKBA. Schwab Charles Investment Management Inc. lifted its holdings in shares of Akebia Therapeutics by 65.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 206,476 shares of the biopharmaceutical company’s stock valued at $2,968,000 after purchasing an additional 81,346 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Akebia Therapeutics by 1.0% during the 2nd quarter. Wells Fargo & Company MN now owns 88,116 shares of the biopharmaceutical company’s stock valued at $1,266,000 after purchasing an additional 880 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Akebia Therapeutics by 157.1% during the 2nd quarter. Alliancebernstein L.P. now owns 43,200 shares of the biopharmaceutical company’s stock valued at $621,000 after purchasing an additional 26,400 shares during the last quarter. Teachers Advisors LLC lifted its holdings in shares of Akebia Therapeutics by 7.1% during the 2nd quarter. Teachers Advisors LLC now owns 68,355 shares of the biopharmaceutical company’s stock valued at $982,000 after purchasing an additional 4,551 shares during the last quarter. Finally, TIAA CREF Investment Management LLC lifted its holdings in shares of Akebia Therapeutics by 144.3% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 252,123 shares of the biopharmaceutical company’s stock valued at $3,623,000 after purchasing an additional 148,940 shares during the last quarter. 62.16% of the stock is currently owned by institutional investors and hedge funds.

AKBA has been the subject of several analyst reports. Piper Jaffray Companies initiated coverage on Akebia Therapeutics in a report on Monday, December 18th. They set an “overweight” rating and a $26.00 price objective for the company. Mizuho reiterated a “buy” rating and set a $24.00 price objective on shares of Akebia Therapeutics in a report on Thursday, November 9th. ValuEngine lowered Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Zacks Investment Research upgraded Akebia Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a report on Monday, November 13th. Finally, BTIG Research initiated coverage on Akebia Therapeutics in a report on Thursday, December 7th. They set a “buy” rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $22.20.

Akebia Therapeutics Inc (NASDAQ:AKBA) opened at $14.47 on Wednesday. Akebia Therapeutics Inc has a 52 week low of $8.58 and a 52 week high of $20.25.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://theolympiareport.com/2018/02/14/mutual-of-america-capital-management-llc-buys-18779-shares-of-akebia-therapeutics-inc-akba.html.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Want to see what other hedge funds are holding AKBA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akebia Therapeutics Inc (NASDAQ:AKBA).

Institutional Ownership by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.